Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Hepatocellular carcinoma (HCC) disproportionately affects racial/ethnic minorities. We evaluated the impact of income and geography on racial/ethnic disparities across the HCC care cascade in the United States.

Methods: Using NCI registry data spanning 2000 to 2020, adults with HCC were evaluated to determine race/ethnicity-specific differences in tumor stage at diagnosis, delays and gaps in treatment, and survival. Adjusted regression models evaluated predictors of HCC outcomes.

Results: Among 112,389 adults with HCC, cohort characteristics were as follows: 49.8% non-Hispanic White (NHW), 12.0% African American(AA), 20.5% Hispanic, 16.5% Asian/Pacific Islander, and 1.1% American Indian/Alaska Native. Compared with NHW patients, AA patients had lower odds of localized-stage HCC at diagnosis [adjusted odds ratio (aOR), 0.84], lower odds of HCC treatment receipt (aOR, 0.77), greater odds of treatment delays (aOR, 1.12), and significantly greater risk of death [adjusted hazards ratio (aHR), 1.10]. Compared with NHW patients from large metro areas, AA patients from large metro areas had 8% higher mortality risk (aHR, 1.08), whereas AA patients from small-medium metro areas had 17% higher mortality risk (aHR, 1.17; all P < 0.05).

Conclusions: Among a population-based cohort of US adults with HCC, significant race/ethnicity-specific disparities across the HCC care continuum were observed. Lower household income and more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients.

Impact: Our study shows that lower income and less urban/more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients with HCC. This contextualizes the complex relationship between sociodemographic factors and HCC outcomes through an intersectional lens.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802308PMC
http://dx.doi.org/10.1158/1055-9965.EPI-24-1094DOI Listing

Publication Analysis

Top Keywords

disparities hcc
16
hcc
13
racial/ethnic minorities
12
geography racial/ethnic
12
adults hcc
12
metro areas
12
hcc outcomes
12
hepatocellular carcinoma
8
sociodemographic factors
8
hcc care
8

Similar Publications

In 2024, a nationwide conflict between the South Korean government and the medical community, the medical-policy conflict, profoundly impacted healthcare delivery. This study aimed to evaluate the changes in the management of hepatocellular carcinoma (HCC) following this crisis. We analyzed retrospective real-world data from university hospitals in the Seoul metropolitan area, supplemented with national healthcare data from the Health Insurance Review and Assessment Service.

View Article and Find Full Text PDF

Introduction And Objectives: Hepatocellular carcinoma (HCC) remains a major health burden in Arab countries, with notable shifts in etiology and epidemiology over recent decades. This study evaluates the changing burden and profile of HCC across 22 Arab nations from 1990 to 2021.

Materials And Methods: We analyzed the Global Burden of Disease (GBD) 2021 data for 22 Arab countries, extracting age-standardized rates (ASR) and estimated annual percentage changes (EAPC) for HCC incidence, prevalence, mortality, and disability-adjusted life years (DALYs), stratified by etiology and gender.

View Article and Find Full Text PDF

Disparities in liver transplantation for metabolic dysfunction-associated steatohepatitis-associated hepatocellular carcinoma.

World J Transplant

September 2025

J C Walter Jr Transplant Center, Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Surgery, Houston Methodist Hospital, Houston, TX 77030, United States.

Background: Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly common, as is hepatocellular carcinoma (HCC) in the background of MASH. Liver transplantation (LT) provides superior long-term survival for patients with unresectable MASH-HCC, but not all patients have equal access to transplant. MASH-HCC disproportionately affects Hispanic patients, but minorities are less likely to undergo LT for HCC.

View Article and Find Full Text PDF

Socioeconomic and demographic predictors of transarterial chemoembolization outcomes for hepatic malignancies.

Curr Probl Diagn Radiol

August 2025

Division of Vascular and Interventional Radiology, Department of Radiology, The Ohio State University Wexner Medical Center, 410 W 10th Avenue Columbus, OH 43210, USA.

Rationale And Objectives: This study aimed to evaluate the socioeconomic and demographic factors that predict overall survival (OS) and progression-free survival (PFS) of patients undergoing transarterial chemoembolization (TACE) for primary and metastatic hepatic disease.

Materials And Methods: Retrospective review from 2016 to 2022 identified 322 patients with hepatocellular carcinoma (HCC) (n = 234) and metastatic liver lesions (n = 98), treated with TACE. Patients were stratified by demographic factors, including mean income, insurance status, race, and social vulnerability index (SVI), a Center for Disease control (CDC) composite measure from geographic census data.

View Article and Find Full Text PDF

Background: Aflatoxin remains an under-recognized hepatocellular‑carcinoma (HCC) risk factor in the United States, where the permissible food limit (20 ppb) is five‑fold higher than in Europe.

Methods:  We analyzed 350 TCGA-HCC cases with whole‑exome, RNA‑seq, and clinical data. Aflatoxin burden was quantified by single-base-substitution signature 24 (SBS24).

View Article and Find Full Text PDF